SAN FRANCISCO (PRWEB) March 12, 2019
Omada Health today announced the inclusion and integration of FDA-cleared, cellular-connected blood pressure cuffs and glucometers for qualifying participants in the company’s chronic condition management program. The integration of these devices will enable individuals to seamlessly upload real-time readings to their Omada account, while providing Omada coaches insight to deliver personalized guidance and ongoing support as participants work to improve their health.
Building on the company’s pioneering approach to sustainable behavior change, Omada will make glucometers and blood pressure cuffs available to any participants clinically recommended to self-monitor blood pressure and glucose levels. Participants who receive the Omada preferred glucometer will also receive as many free test strips as needed. Readings from the devices will be automatically uploaded to a participant’s account, enabling his or her coach to deliver personalized recommendations informed by a wide range of data, and the deep relationship forged with each individual. Participants will also be able to view readings in their account, and track progress over time. The Omada program will also continue to support a ‘bring your own device model’ for participants and customers that prefer the option.
“Our approach - at all levels of our program -- is to provide a unique flexibility that matches the unique circumstances of our participants, while always following clinical best practices,” said Omada VP of Medical Affairs Carolyn Bradner Jasik, MD. “Participants in the Omada program build deep relationships with their coaches; enabling automatic cellular uploading of glucose and blood pressure data will enable those coaches to provide guidance informed by a wide range of data and insights -- helping support the best possible health outcomes.”
When combined with clinical support, self-monitoring of blood pressure improves control, as well as the quality and accessibility of care for people with hypertension. The Centers for Disease Control and Prevention recommends self-monitoring of blood pressure, with similar guidance also coming from the American Medical Association, the American Heart Association, and the American Society of Hypertension. Omada will follow the American Diabetes Association Standards of Care to determine individual eligibility for the cellular glucose monitor.
“At Omada, we follow clinical best practices while delivering excellent participant and customer experiences,” said Sean Duffy, CEO of Omada Health. “Since Day 1, Omada’s program has put the needs of users at its center while driving value for our customers, and the U.S. healthcare system. Our device strategy maintains that focus, and we’re proud to be following the best clinical guidelines in doing so.”
About Omada Health
Omada is a digital behavioral medicine company focused on reducing costly chronic disease in employer and health plan populations. The company offers a personalized intervention for individuals at risk for, or with, obesity-related chronic conditions such as type 2 diabetes and hypertension. Omada is the largest CDC-recognized provider of the National Diabetes Prevention Program, with deep integration experience with leading health plans, outcomes-based pricing, and eleven peer-reviewed studies demonstrating the company’s ability to deliver lasting, clinically-meaningful results. To learn more, visit http://www.omadahealth.com.